A Phase 2 interventional study of Maraviroc and Maraviroc Placebo in Arthritis, Rheumatoid, sponsored by Pfizer. Terminated at 44 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-11-05.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 152 studies in Arthritis, Rheumatoid by Pfizer — 2 open to participants now, 2 under way, none of them phase 3. Arthritis, Rheumatoid · Pfizer.
Among the 152 studies in Arthritis, Rheumatoid by Pfizer, this one is the 48th largest by enrollment of the 86 interventional ones that give a count, is one of 13 that started in 2007, is one of 28 in phase 2, and was the 23rd registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →2 of the 152 studies in Arthritis, Rheumatoid by Pfizer are open now, in 1 country. Recruiting first, the newest first:
Pfizer · Sites in Korea, Republic of
Ages 18+
Pfizer
Ages 18–70
By country, each count listing its studies:
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
152 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 29 · Phase 3 18 · Phase 4 17
First in 2003; this study’s year is marked. 13 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 128 is above the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 155 across the 86 interventional studies, 421 across the 63 observational. Of the 149 that completed or were terminated, 105 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 152 studies in Arthritis, Rheumatoid by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate whether maraviroc, an investigational drug given with methotrexate (MTX) is safe and effective in the treatment of rheumatoid arthritis in adult patients.
Following a planned interim analysis in the POC component on 21 August 2008 by the internal DMC (Data Monitoring Committee) of study A4001056, the trial was discontinued due to lack of efficacy. All participating investigators/country offices and monitors were notified on 22 August 2008 to cease patient enrollment. The DMC indicated that maraviroc was well tolerated in the Rheumatoid Arthritis patients and there were no safety concerns in the study. The termination date of this trial was 07 October 2008 when the last patient last visit occurred.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Maraviroc Placebo
This study was divided into two components: safety/pharmacokinetic (PK) and proof-of-concept (POC). In the safety/PK component either 150 mg or 300 mg tablets of maraviroc was administered twice a day (BID) to 16 rheumatoid arthritis subjects for 4 weeks.
Drug: Maraviroc
300 mg (2- 150 mg tablets) are administered by mouth twice a day (BID) for 12 weeks.
Placebo tablets to match active drug. Two tablets are administered by mouth twice a day (BID) for 12 weeks.
American College of Rheumatology (ACR) 20% Responders at Week 12
A subject was an ACR 20 responder if: the counts for both tender and swollen joints had reduced by 20% or more from baseline; and 3 out of the following 5 assessments showed reduction of 20% or more from baseline assessment: Patient's Assessment of Arthritis Pain (Visual Analogue Scale \[VAS\]), Patient's Global Assessment of Arthritis (VAS), Physician's Global Assessment of Arthritis (Categorical), Health Assessment Questionnaire - Disability Index (HAQ-DI), and C-Reactive Protein (CRP).
Time frame: Week 12
ACR 20% Responders at Weeks 1, 2, 4, and 8
A subject was an ACR 20 responder if: the counts for both tender and swollen joints had reduced by 20% or more from baseline; and 3 out of the following 5 assessments showed reduction of 20% or more from baseline assessment: Patient's Assessment of Arthritis Pain, Patient's Global Assessment of Arthritis, Physician's Global Assessment of Arthritis, HAQ-DI, and CRP. The Week 16 visit (follow-up) was designed for safety rather than efficacy, thus Week 16 ACR 20% data were collected, but not analyzed.
Time frame: Weeks 1, 2, 4, and 8
ACR 50% Responders at Weeks 1, 2, 4, 8, and 12
A subject was an ACR 50 responder if: the counts for both tender and swollen joints had reduced by 50% or more from baseline; and 3 out of the following 5 assessments showed reduction of 50% or more from baseline assessment: Patient's Assessment of Arthritis Pain, Patient's Global Assessment of Arthritis, Physician's Global Assessment of Arthritis, HAQ-DI, and CRP. The Week 16 visit (follow-up) was designed for safety rather than efficacy, thus Week 16 ACR 50% data were collected, but not analyzed.
Time frame: Weeks 1, 2, 4, 8, and 12
ACR 70% Responders at Weeks 1, 2, 4, 8, and 12
A subject was an ACR 70 responder if: the counts for both tender and swollen joints had reduced by 70% or more from baseline; and 3 out of the following 5 assessments showed reduction of 70% or more from baseline assessment: Patient's Assessment of Arthritis Pain, Patient's Global Assessment of Arthritis, Physician's Global Assessment of Arthritis, HAQ-DI, and CRP. The Week 16 visit (follow-up) was designed for safety rather than efficacy, thus Week 16 ACR 70% data were collected, but not analyzed.
Time frame: Weeks 1, 2, 4, 8, and 12
Change From Baseline in Tender/Painful Joint Count at Weeks 1, 2, 4, 8, and 12
Change from baseline at each visit was analyzed for tender/painful joint count. Twenty-eight tender and swollen joint scores included the same joints: shoulders, elbows, wrists, metacarpophalangeal joints (MCP), proximal interphalangeal joints (PIP), and the knees. The Week 16 visit (follow-up) was designed for safety rather than efficacy, thus Week 16 tender/painful joint count data were collected, but not analyzed.
Time frame: Baseline, Weeks 1, 2, 4, 8, and 12
Change From Baseline in Swollen Joint Count at Weeks 1, 2, 4, 8, and 12
Change from baseline at each visit was analyzed for swollen joint count. Twenty-eight tender and swollen joint scores included the same joints: shoulders, elbows, wrists, MCP joints, PIP joints, and the knees. The Week 16 visit (follow-up) was designed for safety rather than efficacy, thus Week 16 swollen joint count data were collected, but not analyzed.
Time frame: Baseline, Weeks 1, 2, 4, 8, and 12
Change From Baseline in Patient's Assessment of Arthritis Pain at Weeks 1, 2, 4, 8, and 12
The severity of arthritis was scored by the subject between 0 (no pain) and 100 (most severe pain) on a 100 mm VAS. Change from baseline at each visit was analyzed for Patient's Assessment of Arthritis Pain. The Week 16 visit (follow-up) was designed for safety rather than efficacy, thus Week 16 Patient's Assessment of Arthritis Pain data were collected, but not analyzed.
Time frame: Baseline, Weeks 1, 2, 4, 8, and 12
Change From Baseline in Patient's Global Assessment of Arthritis Pain at Weeks 1, 2, 4, 8, and 12
Subjects answered: "Considering all the ways your arthritis affects you, how are you feeling today?" Subjects responded by using a 0 - 100 mm VAS where 0=very well and 100=very poorly. Change from baseline at each visit was analyzed for Patient's Global Assessment. The Week 16 visit (follow-up) was designed for safety rather than efficacy, thus Week 16 Patient's Global Assessment of Arthritis Pain data were collected, but not analyzed.
Time frame: Baseline, Weeks 1, 2, 4, 8, and 12
Change From Baseline in Physician's Global Assessment of Arthritis Pain at Weeks 1, 2, 4, 8, and 12
Physician's evaluation based on subject's disease signs, functional capacity and physical exam. Response recorded using 5-point scale: 1=Very Good, 2=Good, 3=Fair, 4=Poor and 5=Very Poor. Change from baseline at each visit was analyzed for Physician's Global Assessment. The Week 16 visit (follow-up) was designed for safety rather than efficacy thus Week 16 Physician's Global Assessment of Arthritis Pain data were collected but not analyzed.
Time frame: Baseline, Weeks 1, 2, 4, 8, and 12
Change From Baseline in HAQ-DI at Weeks 1, 2, 4, 8, and 12
HAQ-DI assesses degree of difficulty experienced in daily activity categories (dressing/grooming, arising, eating, walking, hygiene, reach, grip and other activities) over the past week. There are 20 questions and difficulty is scored from 0 (none), 1 (some), 2 (much) and 3 (unable to do). Scores were then averaged to give the disability index (scale of 0 to 3). Change from baseline at each visit was analyzed. The Week 16 visit (follow-up) was designed for safety rather than efficacy, thus Week 16 HAQ-DI data were collected but not analyzed.
Time frame: Baseline, Weeks 1, 2, 4, 8, and 12
Change From Baseline in CRP at Weeks 1, 2, 4, 8, and 12
Change from baseline at each visit were analyzed for CRP. The Week 16 visit (follow-up) was designed for safety rather than efficacy, thus Week 16 CRP data were collected, but not analyzed.
Time frame: Baseline, Weeks 1, 2, 4, 8, and 12
Change From Baseline in Disease Activity Score Using CRP (DAS28-4[CRP]) at Weeks 1, 2, 4, 8, and 12
DAS28-4 (CRP) was calculated using the following formula: DAS28- 4(CRP) = 0.56 √28 Tender Joint Count + 0.28 √28 Swollen Joint Count + 0.36\*natural logarithm(CRP + 1) + 0.014\*Patient Global Assessment + 0.96. DAS28 provides a number on a scale (0 to 10) indicating current disease activity. A score above 5.1 means high disease activity and a score below 3.2 indicates low disease activity. Change from baseline at each visit was analyzed for DAS28-4 (CRP). The Week 16 visit (follow-up) was designed for safety rather than efficacy, thus Week 16 DAS28-4 (CRP) data were collected, but not analyzed.
Time frame: Baseline, Weeks 1, 2, 4, 8, and 12
Change From Baseline in Mean Orthostatic Blood Pressure (BP)
Supine BP was recorded after 5 minutes lying down; subjects then sat for 2 minutes then stood for 2 minutes and standing BP was recorded. Orthostatic BP = either a systolic BP drop \> 20 mmHg, or diastolic BP drop \> 10 mmHg and/or drop in systolic BP \< 90 mmHg. If a subject met the orthostatic criteria, they were required to complete 2 additional readings to provide a triplicate reading. The means of replicate BP values were used in the analysis. Baseline = the latest non-missing value from a range of pre-treatment visits. Change from baseline to Week 16 was analyzed for orthostatic BP.
Time frame: Baseline, 16 weeks
Change From Baseline in Mean Heart Rate
Heart rate = standing and supine at the same time the orthostatic BP measurements were obtained. Baseline was defined to be the latest non-missing value from a range of pre-treatment visits. Means of replicate values were not used.
Time frame: Baseline, 16 weeks
Number of Subjects With Categorical Absolute Vital Signs and Vital Sign Changes Compared to Baseline
Baseline was defined to be the latest non-missing value from a range of pre-treatment visits. Maximum increase from baseline in supine and standing systolic BP was \> = 30 mmHg, and maximum increase from baseline in supine and standing diastolic BP was \> = 20 mmHg.
Time frame: Baseline, 16 weeks
Change From Baseline in 12-Lead Electrocardiogram (ECG) Parameters (RR Interval, PR Interval, QRS Complex, QT Interval, Corrected QT [QTc] Interval, QTcB Interval [Bazett's Correction], QTcF Interval [Fridericia's Correction]).
Baseline was defined to be the latest non-missing value from a range of pre-treatment visits. Means of replicate values were used. QTc interval was not measured for the PK populations.
Time frame: Baseline, 16 weeks
Change From Baseline in 12-Lead Electrocardiogram (ECG) Parameters (Heart Rate).
Baseline was defined to be the latest non-missing value from a range of pre-treatment visits. Means of replicate values were used.
Time frame: Baseline, 16 weeks
Number of Subjects With Categorical Absolute ECG Parameters and ECG Changes Compared to Baseline
Maximum QTcB, QTcF, and QTc intervals were defined as 450 to \< 480 msec, 480 to \< 500 msec, or \> = 500 msec.
Time frame: Baseline, 16 weeks
Change From Baseline in Short Form-36 (SF-36) Physical Component Summary at Weeks 4 and 12
The SF-36 v.2 (Acute version) is a 36-item generic health status measure that measures 8 general health concepts: Physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. Each domain of the eight domains and the summary concept (physical component score) are scored to yield values between 0 (worst) and 100 (best). Change from baseline at Weeks 4 and 12 were analyzed for SF-36. Due to the termination of the study, SF-36 results for the PK component group were not analyzed.
Time frame: Baseline, Weeks 4 and 12
Change From Baseline in SF-36 Mental Component Summary at Weeks 4 and 12
The SF-36 v.2 (Acute version) \[12\] is a 36-item generic health status measure that measures 8 general health concepts: Physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. Each domain of the eight domains and the summary concept (mental component score) are scored to yield values between 0 (worst) and 100 (best). Change from baseline at Weeks 4 and 12 were analyzed for SF-36. Due to the termination of the study, SF-36 results for the PK component group were not analyzed.
Time frame: Baseline, Weeks 4 and 12
Number of Subjects With Withdrawal From Study Due to Lack of Efficacy
Withdrawal is the total number of withdrawals from the study. Withdrawal due to lack of efficacy was collected based on the investigator's judgement.
Time frame: 16 weeks
Survival Analysis of Time to Withdrawal: Proportion of Subjects Who Did Not Withdraw From the Study Due to Lack of Efficacy.
Withdrawal due to lack of efficacy was collected based on the investigator's judgement. Time to withdrawal was measured by the probability that a subject did not withdraw due to lack of efficacy by a particular visit. This was a statistical estimate (Kaplan-Meier Survival Analysis) of the probability that a participant would not withdraw due to lack of efficacy.
Time frame: Weeks 1 to 12
Area Under the Plasma Concentration-Time Profile From Time Zero to Four Hours Postdose (AUC 0-4) for MTX at Screening and Week 1 and Maraviroc at Week 1
Effect of maraviroc on the PK of MTX (comparison of AUC0-4 of MTX at screening versus at Week 1 after coadministration with 150 mg or 300 mg of maraviroc). PK was assessed at screening (MTX) and at Week 1 (maraviroc and MTX).
Time frame: Screening (1, 2, 3, and 4 hours post-dose), Week 1 (0.5, 1, 2, 3, and 4 hours post-dose)
Maximum Observed Concentration (Cmax) During the Dosing Interval for MTX at Screening and Week 1 and Maraviroc at Week 1
Effect of maraviroc on the PK of MTX (comparison of Cmax of MTX at screening versus at Week 1 after coadministration with 150 mg or 300 mg of maraviroc). PK was assessed at screening (MTX) and at Week 1 (maraviroc and MTX).
Time frame: Screening (1, 2, 3, and 4 hours post-dose), Week 1 (0.5, 1, 2, 3, and 4 hours post-dose)
Time for Cmax (Tmax) for MTX at Screening and Week 1 and Maraviroc at Week 1
PK was assessed at screening (MTX) and at Week 1 (maraviroc and MTX).
Time frame: Screening (1, 2, 3, and 4 hours post-dose), Week 1 (0.5, 1, 2, 3, and 4 hours post-dose)
| Milestone | Maraviroc 150 mg BID (Pharmacokinetic [PK]) | Maraviroc 300 mg BID (PK) | Maraviroc 300 mg BID (Proof-of-Concept [POC]) | Placebo (POC) |
|---|---|---|---|---|
| Started | 8 | 8 | 78 | 34 |
| Treated | 8 | 8 | 77 | 33 |
| Completed | 7 | 8 | 55 | 19 |
| Not completed | 1 | 0 | 23 | 15 |
| Withdrew: Adverse event | 1 | 0 | 5 | 4 |
| Withdrew: Lack of efficacy | 0 | 0 | 5 | 2 |
| Withdrew: Randomized but did not receive treatment | 0 | 0 | 1 | 1 |
| Withdrew: Other | 0 | 0 | 11 | 5 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 3 |
A subject was an ACR 20 responder if: the counts for both tender and swollen joints had reduced by 20% or more from baseline; and 3 out of the following 5 assessments showed reduction of 20% or more from baseline assessment: Patient's Assessment of Arthritis Pain, Patient's Global Assessment of Arthritis, Physician's Global Assessment of Arthritis, HAQ-DI, and CRP. The Week 16 visit (follow-up) was designed for safety rather than efficacy, thus Week 16 ACR 20% data were collected, but not analyzed.
| Participants | Maraviroc 300 mg BID (POC) | Placebo (POC) |
|---|---|---|
| Week 1 | 8 | 4 |
| Week 2 | 12 | 5 |
| Week 4 | 21 | 8 |
| Week 8 | 23 | 7 |
A subject was an ACR 50 responder if: the counts for both tender and swollen joints had reduced by 50% or more from baseline; and 3 out of the following 5 assessments showed reduction of 50% or more from baseline assessment: Patient's Assessment of Arthritis Pain, Patient's Global Assessment of Arthritis, Physician's Global Assessment of Arthritis, HAQ-DI, and CRP. The Week 16 visit (follow-up) was designed for safety rather than efficacy, thus Week 16 ACR 50% data were collected, but not analyzed.
| Participants | Maraviroc 300 mg BID (POC) | Placebo (POC) |
|---|---|---|
| Week 1 | 1 | 0 |
| Week 2 | 2 | 0 |
| Week 4 | 2 | 2 |
| Week 8 | 6 | 3 |
| Week 12 | 8 | 3 |
A subject was an ACR 70 responder if: the counts for both tender and swollen joints had reduced by 70% or more from baseline; and 3 out of the following 5 assessments showed reduction of 70% or more from baseline assessment: Patient's Assessment of Arthritis Pain, Patient's Global Assessment of Arthritis, Physician's Global Assessment of Arthritis, HAQ-DI, and CRP. The Week 16 visit (follow-up) was designed for safety rather than efficacy, thus Week 16 ACR 70% data were collected, but not analyzed.
| Participants | Maraviroc 300 mg BID (POC) | Placebo (POC) |
|---|---|---|
| Week 1 | 0 | 0 |
| Week 2 | 0 | 0 |
| Week 4 | 0 | 1 |
| Week 8 | 2 | 0 |
| Week 12 | 0 | 1 |
Change from baseline at each visit was analyzed for tender/painful joint count. Twenty-eight tender and swollen joint scores included the same joints: shoulders, elbows, wrists, metacarpophalangeal joints (MCP), proximal interphalangeal joints (PIP), and the knees. The Week 16 visit (follow-up) was designed for safety rather than efficacy, thus Week 16 tender/painful joint count data were collected, but not analyzed.
| joint count | Maraviroc 300 mg BID (POC) | Placebo (POC) |
|---|---|---|
| Week 1 | -0.81 ± 0.68 | -1.91 ± 0.96 |
| Week 2 | -2.08 ± 0.76 | -2.38 ± 1.08 |
| Week 4 | -4.00 ± 0.84 | -4.01 ± 1.20 |
| Week 8 | -4.85 ± 0.85 | -3.24 ± 1.21 |
| Week 12 | -4.89 ± 0.84 | -3.41 ± 1.19 |
Change from baseline at each visit was analyzed for swollen joint count. Twenty-eight tender and swollen joint scores included the same joints: shoulders, elbows, wrists, MCP joints, PIP joints, and the knees. The Week 16 visit (follow-up) was designed for safety rather than efficacy, thus Week 16 swollen joint count data were collected, but not analyzed.
| joint count | Maraviroc 300 mg BID (POC) | Placebo (POC) |
|---|---|---|
| Week 1 | -1.39 ± 0.49 | -1.07 ± 0.70 |
| Week 2 | -2.25 ± 0.61 | -2.51 ± 0.87 |
| Week 4 | -3.93 ± 0.54 | -4.08 ± 0.77 |
| Week 8 | -4.48 ± 0.62 | -3.03 ± 0.88 |
| Week 12 | -3.48 ± 0.66 | -3.43 ± 0.95 |
The severity of arthritis was scored by the subject between 0 (no pain) and 100 (most severe pain) on a 100 mm VAS. Change from baseline at each visit was analyzed for Patient's Assessment of Arthritis Pain. The Week 16 visit (follow-up) was designed for safety rather than efficacy, thus Week 16 Patient's Assessment of Arthritis Pain data were collected, but not analyzed.
| scores on scale | Maraviroc 300 mg BID (POC) | Placebo (POC) |
|---|---|---|
| Week 1 | -3.96 ± 2.18 | -3.62 ± 3.10 |
| Week 2 | -8.46 ± 2.65 | -3.20 ± 3.77 |
| Week 4 | -8.35 ± 2.70 | -9.08 ± 3.85 |
| Week 8 | -10.30 ± 2.98 | -8.67 ± 4.24 |
| Week 12 | -8.30 ± 2.85 | -6.09 ± 4.06 |
Subjects answered: "Considering all the ways your arthritis affects you, how are you feeling today?" Subjects responded by using a 0 - 100 mm VAS where 0=very well and 100=very poorly. Change from baseline at each visit was analyzed for Patient's Global Assessment. The Week 16 visit (follow-up) was designed for safety rather than efficacy, thus Week 16 Patient's Global Assessment of Arthritis Pain data were collected, but not analyzed.
| scores on scale | Maraviroc 300 mg BID (POC) | Placebo (POC) |
|---|---|---|
| Week 1 | -4.70 ± 2.22 | -2.34 ± 3.13 |
| Week 2 | -8.85 ± 2.48 | -4.88 ± 3.49 |
| Week 4 | -10.00 ± 2.74 | -9.02 ± 3.86 |
| Week 8 | -11.12 ± 2.93 | -3.44 ± 4.13 |
| Week 12 | -8.55 ± 2.88 | -6.78 ± 4.06 |
Physician's evaluation based on subject's disease signs, functional capacity and physical exam. Response recorded using 5-point scale: 1=Very Good, 2=Good, 3=Fair, 4=Poor and 5=Very Poor. Change from baseline at each visit was analyzed for Physician's Global Assessment. The Week 16 visit (follow-up) was designed for safety rather than efficacy thus Week 16 Physician's Global Assessment of Arthritis Pain data were collected but not analyzed.
| scores on scale | Maraviroc 300 mg BID (POC) | Placebo (POC) |
|---|---|---|
| Week 1 | -0.30 ± 0.08 | -0.22 ± 0.11 |
| Week 2 | -0.44 ± 0.09 | -0.39 ± 0.12 |
| Week 4 | -0.49 ± 0.10 | -0.44 ± 0.13 |
| Week 8 | -0.63 ± 0.10 | -0.37 ± 0.14 |
| Week 12 | -0.49 ± 0.11 | -0.36 ± 0.15 |
HAQ-DI assesses degree of difficulty experienced in daily activity categories (dressing/grooming, arising, eating, walking, hygiene, reach, grip and other activities) over the past week. There are 20 questions and difficulty is scored from 0 (none), 1 (some), 2 (much) and 3 (unable to do). Scores were then averaged to give the disability index (scale of 0 to 3). Change from baseline at each visit was analyzed. The Week 16 visit (follow-up) was designed for safety rather than efficacy, thus Week 16 HAQ-DI data were collected but not analyzed.
| scores on scale | Maraviroc 300 mg BID (POC) | Placebo (POC) |
|---|---|---|
| Week 1 | -0.08 ± 0.05 | -0.03 ± 0.07 |
| Week 2 | -0.22 ± 0.06 | -0.04 ± 0.08 |
| Week 4 | -0.24 ± 0.06 | -0.18 ± 0.09 |
| Week 8 | -0.25 ± 0.07 | -0.03 ± 0.10 |
| Week 12 | -0.18 ± 0.08 | -0.06 ± 0.13 |
Change from baseline at each visit were analyzed for CRP. The Week 16 visit (follow-up) was designed for safety rather than efficacy, thus Week 16 CRP data were collected, but not analyzed.
| mg/L | Maraviroc 300 mg BID (POC) | Placebo (POC) |
|---|---|---|
| Week 1 | 1.20 ± 1.87 | 3.40 ± 2.67 |
| Week 2 | 3.14 ± 2.06 | 1.81 ± 2.93 |
| Week 4 | 3.36 ± 2.34 | -1.30 ± 3.33 |
| Week 8 | 2.33 ± 2.10 | -1.14 ± 2.98 |
| Week 12 | 2.35 ± 2.26 | 1.93 ± 3.22 |
DAS28-4 (CRP) was calculated using the following formula: DAS28- 4(CRP) = 0.56 √28 Tender Joint Count + 0.28 √28 Swollen Joint Count + 0.36\*natural logarithm(CRP + 1) + 0.014\*Patient Global Assessment + 0.96. DAS28 provides a number on a scale (0 to 10) indicating current disease activity. A score above 5.1 means high disease activity and a score below 3.2 indicates low disease activity. Change from baseline at each visit was analyzed for DAS28-4 (CRP). The Week 16 visit (follow-up) was designed for safety rather than efficacy, thus Week 16 DAS28-4 (CRP) data were collected, but not analyzed.
| mg/L | Maraviroc 300 mg BID (POC) | Placebo (POC) |
|---|---|---|
| Week 1 | -0.23 ± 0.09 | -0.17 ± 0.13 |
| Week 2 | -0.41 ± 0.12 | -0.33 ± 0.17 |
| Week 4 | -0.64 ± 0.14 | -0.65 ± 0.19 |
| Week 8 | -0.82 ± 0.15 | -0.51 ± 0.21 |
| Week 12 | -0.73 ± 0.16 | -0.63 ± 0.22 |
Supine BP was recorded after 5 minutes lying down; subjects then sat for 2 minutes then stood for 2 minutes and standing BP was recorded. Orthostatic BP = either a systolic BP drop \> 20 mmHg, or diastolic BP drop \> 10 mmHg and/or drop in systolic BP \< 90 mmHg. If a subject met the orthostatic criteria, they were required to complete 2 additional readings to provide a triplicate reading. The means of replicate BP values were used in the analysis. Baseline = the latest non-missing value from a range of pre-treatment visits. Change from baseline to Week 16 was analyzed for orthostatic BP.
| mmHg | Maraviroc 150 mg BID (PK) | Maraviroc 300 mg BID (PK) | Maraviroc 300 mg BID (POC) | Placebo (POC) |
|---|---|---|---|---|
| Standing Systolic BP | 20.9 ± 13.18 | 18.0 ± 7.71 | 17.8 ± 11.25 | 17.5 ± 12.36 |
| Supine Systolic BP | 20.9 ± 13.58 | 18.3 ± 9.51 | 17.5 ± 13.86 | 18.0 ± 11.12 |
| Standing Diastolic BP | 13.0 ± 4.97 | 8.3 ± 5.65 | 11.7 ± 6.98 | 11.5 ± 5.15 |
| Supine Diastolic BP | 10.3 ± 7.94 | 10.9 ± 5.08 | 12.2 ± 8.14 | 10.8 ± 5.12 |
A subject was an ACR 20 responder if: the counts for both tender and swollen joints had reduced by 20% or more from baseline; and 3 out of the following 5 assessments showed reduction of 20% or more from baseline assessment: Patient's Assessment of Arthritis Pain (Visual Analogue Scale \[VAS\]), Patient's Global Assessment of Arthritis (VAS), Physician's Global Assessment of Arthritis (Categorical), Health Assessment Questionnaire - Disability Index (HAQ-DI), and C-Reactive Protein (CRP).
| Participants | Maraviroc 300 mg BID (POC) | Placebo (POC) |
|---|---|---|
| American College of Rheumatology (ACR) 20% Responders at Week 12 | 21 | 6 |
Heart rate = standing and supine at the same time the orthostatic BP measurements were obtained. Baseline was defined to be the latest non-missing value from a range of pre-treatment visits. Means of replicate values were not used.
| beats per minute (bpm) | Maraviroc 150 mg BID (PK) | Maraviroc 300 mg BID (PK) | Maraviroc 300 mg BID (POC) | Placebo (POC) |
|---|---|---|---|---|
| Standing Heart Rate | 14.6 ± 6.73 | 8.1 ± 3.64 | 11.8 ± 6.91 | 11.4 ± 8.13 |
| Supine Heart Rate | 15.0 ± 8.28 | 10.4 ± 4.56 | 11.6 ± 6.06 | 9.2 ± 6.16 |
Baseline was defined to be the latest non-missing value from a range of pre-treatment visits. Maximum increase from baseline in supine and standing systolic BP was \> = 30 mmHg, and maximum increase from baseline in supine and standing diastolic BP was \> = 20 mmHg.
| Participants | Maraviroc 150 mg BID (PK) | Maraviroc 300 mg BID (PK) | Maraviroc 300 mg BID (POC) | Placebo (POC) |
|---|---|---|---|---|
| Maximum Increase in Supine Systolic BP | 2 | 1 | 4 | 3 |
| Maximum Increase in Standing Systolic BP | 1 | 1 | 2 | 2 |
| Maximum Increase in Supine Diastolic BP | 1 | 1 | 8 | 0 |
| Maximum Increase in Standing Diastolic BP | 0 | 0 | 3 | 2 |
Baseline was defined to be the latest non-missing value from a range of pre-treatment visits. Means of replicate values were used. QTc interval was not measured for the PK populations.
| msec | Maraviroc 150 mg BID (PK) | Maraviroc 300 mg BID (PK) | Maraviroc 300 mg BID (POC) | Placebo (POC) |
|---|---|---|---|---|
| RR Interval | 137.0 ± 79.18 | 114.3 ± 63.38 | 140.0 ± 70.81 | 117.6 ± 48.26 |
| PR Interval | 19.7 ± 7.13 | 13.0 ± 6.93 | 16.2 ± 8.00 | 15.4 ± 10.47 |
| QRS Complex | 7.6 ± 4.75 | 7.3 ± 4.89 | 11.3 ± 6.56 | 10.2 ± 5.35 |
| QT Interval | 35.0 ± 19.47 | 22.5 ± 10.67 | 31.9 ± 18.74 | 28.7 ± 13.97 |
| QTc Interval | 0 ± 0 | 0 ± 0 | 19.6 ± 17.69 | 20.3 ± 12.75 |
| QTcB Interval | 23.1 ± 19.70 | 23.3 ± 9.55 | 27.9 ± 18.47 | 30.2 ± 23.88 |
| QTcF Interval | 22.9 ± 19.64 | 17.3 ± 7.16 | 28.3 ± 18.77 | 29.8 ± 22.20 |
Baseline was defined to be the latest non-missing value from a range of pre-treatment visits. Means of replicate values were used.
| bpm | Maraviroc 150 mg BID (PK) | Maraviroc 300 mg BID (PK) | Maraviroc 300 mg BID (POC) | Placebo (POC) |
|---|---|---|---|---|
| Change From Baseline in 12-Lead Electrocardiogram (ECG) Parameters (Heart Rate). | 11.2 ± 5.82 | 8.8 ± 5.76 | 12.0 ± 6.40 | 10.5 ± 4.91 |
Maximum QTcB, QTcF, and QTc intervals were defined as 450 to \< 480 msec, 480 to \< 500 msec, or \> = 500 msec.
| Participants | Maraviroc 150 mg BID (PK) | Maraviroc 300 mg BID (PK) | Maraviroc 300 mg BID (POC) | Placebo (POC) |
|---|---|---|---|---|
| Maximum QTc Interval 450 to < 480 msec | 0 | 0 | 2 | 2 |
| Maximum QTc Interval 480 to < 500 msec | 0 | 0 | 0 | 0 |
| Maximum QTc Interval > = 500 msec | 0 | 0 | 0 | 0 |
| Maximum QTcB Interval 450 to < 480 msec | 1 | 3 | 13 | 8 |
| Maximum QTcB Interval 480 to < 500 msec | 0 | 0 | 2 | 1 |
| Maximum QTcB Interval > = 500 msec | 0 | 0 | 0 | 1 |
| Maximum QTcF Interval 450 to < 480 msec | 0 | 2 | 9 | 5 |
| Maximum QTcF Interval 480 to < 500 msec | 0 | 0 | 0 | 0 |
| Maximum QTcF Interval > = 500 msec | 0 | 0 | 0 | 0 |
The SF-36 v.2 (Acute version) is a 36-item generic health status measure that measures 8 general health concepts: Physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. Each domain of the eight domains and the summary concept (physical component score) are scored to yield values between 0 (worst) and 100 (best). Change from baseline at Weeks 4 and 12 were analyzed for SF-36. Due to the termination of the study, SF-36 results for the PK component group were not analyzed.
| scores on a scale | Maraviroc 300 mg BID (POC) | Placebo (POC) |
|---|---|---|
| Week 4 | 4.33 ± 0.89 | 3.76 ± 1.25 |
| Week 12 | 3.14 ± 1.04 | 4.81 ± 1.65 |
The SF-36 v.2 (Acute version) \[12\] is a 36-item generic health status measure that measures 8 general health concepts: Physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. Each domain of the eight domains and the summary concept (mental component score) are scored to yield values between 0 (worst) and 100 (best). Change from baseline at Weeks 4 and 12 were analyzed for SF-36. Due to the termination of the study, SF-36 results for the PK component group were not analyzed.
| scores on a scale | Maraviroc 300 mg BID (POC) | Placebo (POC) |
|---|---|---|
| Week 4 | 1.42 ± 1.25 | 0.72 ± 1.75 |
| Week 12 | 1.17 ± 1.41 | 0.61 ± 2.25 |
Withdrawal is the total number of withdrawals from the study. Withdrawal due to lack of efficacy was collected based on the investigator's judgement.
| participants | Maraviroc 300 mg BID (POC) | Placebo (POC) |
|---|---|---|
| Overall Withdrawal | 22 | 14 |
| Withdrawal due to Lack of Efficacy | 5 | 2 |
Withdrawal due to lack of efficacy was collected based on the investigator's judgement. Time to withdrawal was measured by the probability that a subject did not withdraw due to lack of efficacy by a particular visit. This was a statistical estimate (Kaplan-Meier Survival Analysis) of the probability that a participant would not withdraw due to lack of efficacy.
| proportion | Maraviroc 300 mg BID (POC) | Placebo (POC) |
|---|---|---|
| Week 1 (n=77, 33) | 1.00 | 1.00 |
| Week 2 (n=77, 32) | 1.00 | 1.00 |
| Week 4 (n=76, 32) | 1.00 | 1.00 |
| Week 8 (n=69, 31) | 0.99 | 1.00 |
| Week 12 (n=58, 21) | 0.93 | 0.92 |
Effect of maraviroc on the PK of MTX (comparison of AUC0-4 of MTX at screening versus at Week 1 after coadministration with 150 mg or 300 mg of maraviroc). PK was assessed at screening (MTX) and at Week 1 (maraviroc and MTX).
| ng.hr/mL | Maraviroc 150 mg BID (PK) | Maraviroc 300 mg BID (PK) |
|---|---|---|
| Plasma MTX (Screening) | 909.4 ± 422.37 | 888.9 ± 249.51 |
| Plasma MTX (Week 1) | 1045.6 ± 329.93 | 844.8 ± 273.92 |
| Plasma Maraviroc (Week 1) | 451.6 ± 247.33 | 1106.8 ± 1029.60 |
Effect of maraviroc on the PK of MTX (comparison of Cmax of MTX at screening versus at Week 1 after coadministration with 150 mg or 300 mg of maraviroc). PK was assessed at screening (MTX) and at Week 1 (maraviroc and MTX).
| ng/mL | Maraviroc 150 mg BID (PK) | Maraviroc 300 mg BID (PK) |
|---|---|---|
| Plasma MTX (Screening) | 338.7 ± 143.94 | 352.1 ± 115.72 |
| Plasma MTX (Week 1) | 403.8 ± 97.46 | 322.8 ± 104.20 |
| Plasma Maraviroc (Week 1) | 199.59 ± 115.603 | 461.03 ± 365.715 |
PK was assessed at screening (MTX) and at Week 1 (maraviroc and MTX).
| hr | Maraviroc 150 mg BID (PK) | Maraviroc 300 mg BID (PK) |
|---|---|---|
| Plasma MTX (Screening) | 2.000 (1.00 to 3.00) | 1.000 (1.00 to 3.00) |
| Plasma MTX (Week 1) | 1.000 (0.50 to 2.00) | 1.500 (0.50 to 2.00) |
| Plasma Maraviroc (Week 1) | 2.000 (0.50 to 3.00) | 2.500 (1.00 to 4.00) |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Maraviroc 150 mg BID (PK) | — | 0/8 (0%) | 4/8 (50%) |
| Maraviroc 300 mg BID (PK) | — | 0/8 (0%) | 4/8 (50%) |
| Maraviroc 300 mg BID (POC) | — | 0/77 (0%) | 39/77 (50.6%) |
| Placebo (POC) | — | 0/33 (0%) | 21/33 (63.6%) |
| Event | Maraviroc 150 mg BID (PK) | Maraviroc 300 mg BID (PK) | Maraviroc 300 mg BID (POC) | Placebo (POC) |
|---|---|---|---|---|
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/8 | 0/8 | 0/77 | 1/33 |
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 0/8 | 0/8 | 3/77 | 8/33 |
| Dry mouthGastrointestinal disorders | 0/8 | 1/8 | 1/77 | 1/33 |
| NauseaGastrointestinal disorders | 1/8 | 0/8 | 4/77 | 0/33 |
| FatigueGeneral disorders | 1/8 | 0/8 | 3/77 | 0/33 |
| SinusitisInfections and infestations | 0/8 | 1/8 | 0/77 | 1/33 |
| Upper respiratory tract infectionInfections and infestations | 0/8 | 1/8 | 3/77 | 0/33 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 1/8 | 1/8 | 0/77 | 1/33 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 0/8 | 1/8 | 1/77 | 1/33 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 0/8 | 1/8 | 1/77 | 0/33 |
| Age, Customized(Participants) | Maraviroc 150 mg BID (PK) | Maraviroc 300 mg BID (PK) | Maraviroc 300 mg BID (POC) | Placebo (POC) | Total |
|---|---|---|---|---|---|
| < 18 years | 0 | 0 | 0 | 0 | 0 |
| 18 to 44 years | 1 | 0 | 15 | 6 | 22 |
| 45 to 64 years | 4 | 8 | 48 | 21 | 81 |
| > = 65 years | 3 | 0 | 14 | 6 | 23 |
| Sex: Female, Male(Participants) | Maraviroc 150 mg BID (PK) | Maraviroc 300 mg BID (PK) | Maraviroc 300 mg BID (POC) | Placebo (POC) | Total |
|---|---|---|---|---|---|
| Female | 4 | 5 | 71 | 22 | 102 |
| Male | 4 | 3 | 6 | 11 | 24 |
The record gives a start of Feb 2007, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2010, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Maraviroc